| |
Dataset name
|
Dataset ID
|
N° of state changes (SC)
|
N°of HYPs in dataset
|
NoHYPs overlapping withEC activation
|
N° HYPs overlapping withplatelet activation
|
N° HYPs overlapping withEC-monocyte interaction
|
N° HYPs overlapping withfoam cell formation
|
N° HYPs O/L with SMC Activation
|
N° HYPs O/L with Plaque Destabilization
|
N° HYPs O/L with V-IPN
|
|---|
|
Total N°
of possible HYPs in each subnetwork for human/mouse
|
2410/ 2354
|
155/149
|
59/55
|
30/27
|
118/113
|
88/84
|
104/102
|
340*/334
|
|
Mouse
|
Mm_Ao_78w_ApoE_vs_wt
|
GSE10000
|
3872
|
449
|
59
|
11
|
13
|
42
|
32
|
43
|
110
|
|
Mm_Ao_16w_ApoE_CS_vs_sham
|
E-MTAB-1696
|
1928
|
245
|
24
|
8
|
4
|
23
|
19
|
18
|
52
|
|
Human
|
Hs_EC_GFP_oxLDL_vs_ct
|
GSE13139
|
398
|
152
|
16
|
4
|
4
|
16
|
9
|
14
|
31
|
|
Hs_EC_LOX1_oxLDL_vs_ct
|
GSE13139
|
752
|
224
|
30
|
8
|
8
|
21
|
16
|
21
|
52
|
|
Hs_EC_oxPAP_vs_ct
|
GSE20060
|
609
|
309
|
45
|
12
|
8
|
21
|
23
|
27
|
77
|
|
Hs_athCA_vs_ctIMA
|
GSE40231
|
3643
|
309
|
42
|
17
|
11
|
36
|
20
|
37
|
80
|
|
Hs_NHBE_CDKinh_rel_vs_blk_8h
|
E-MTAB-1272
|
1655
|
296
|
27
|
5
|
7
|
19
|
18
|
14
|
53
|
|
Hs_MVEC-C_hpx_vs_ct_24h
|
GSE11341
|
459
|
192
|
27
|
8
|
4
|
16
|
16
|
18
|
48
|
|
Hs_MVEC-L_hpx_vs_ct_24h
|
GSE11341
|
504
|
198
|
22
|
4
|
4
|
15
|
13
|
14
|
42
|
| |
Hs_JurkT_ars_vs_ct
|
GSE46909
|
2381
|
157
|
15
|
5
|
3
|
3
|
9
|
8
|
31
|
- Reverse causal reasoning (RCR) analysis was conducted using richness and concordance p values <0.05. HYPs that met both criteria were considered to be statistically significant. *Total number of unique human HYPs among the six subnetworks. Total is not 551 HYPs, the sum obtained from Figure 3, due to node/HYP overlap between the subnetworks. Mm_Ao_78w_ApoE_vs_wt (GSE10000) is included in this table as a building dataset reference. O/L: overlapping. Dataset Name Dataset ID N° of state changes (SC) N° of HYPs in dataset N° HYPs O/L with EC Activation N° HYPs O/L with Platelet Activation N° HYPs O/L with EC-Monocyte Interaction N° HYPs O/L with Foam Cell Formation N° HYPs O/L with SMC Activation N° HYPs O/L with Plaque Destabilization N° HYPs O/L with V-IPN.
